The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...

CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

If you think last week's decision by the federal government to halt $500 million in funding for vaccine development projects that use mRNA technology will only affect COVID vaccines, think again.

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

CREATE Medicines, Inc. (formerly Myeloid Therapeutics) today announced new preclinical data for RetroT, the company's fully RNA-encoded, site-specific gene-integration system, presented at the Cold ...

By halting funding for mRNA research, the government is endangering America’s health and leadership in biomedical innovation.

SAN DIEGO & BRISBANE, Calif.--(BUSINESS WIRE)--VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a non-exclusive license agreement with Mammoth Biosciences, ...

A lthough still in its early days, CRISPR has already been called the most powerful scientific tool of the century. Using ...

The influenza A virus (IAV) has been the cause of six major flu pandemics, responsible for 50 to 100 million deaths globally. In the U.S. alone, it is estimated that despite seasonally updated ...